Teams

The NIHR Bristol CRF is currently focusing resources on developing two areas of clinical research, these are Vaccine development and testing and Oncology and immune therapy.

Vaccine development and testing team

Formed in the early stages of the COVID19 pandemic and including clinical and non-clinical research staff from across the trust, this site team rapidly and successfully delivered a number of clinical trials which made a significant contribution to the UK’s pandemic response.

In recent months, they have expanded their portfolio to include vaccines for other diseases, including E. Coli; CMV, RSV and paratyphoid. They have also conducted safety studies looking into the co-administration of vaccines.

This team includes two NIHR CRF funded Early phase specialist nurses.

Oncology and immune therapy team

The NIHR CRF part-funded oncology Early Phase/Complex trial delivery team is based in the Clinical Trials Unit (CTU) at Bristol Oncology and Haematology Centre (BHOC) which is a short walk away from the NIHR Bristol CRF building.

The team is comprised of a Band 7 Senior Research nurse, Band 6 Clinical Research practitioner and Band 5 Chemotherapy Research nurse working alongside over 40 experienced research professionals within the established BHOC Clinical Trials Unit (CTU).

This team has demonstrated an excellent track record of multi-centre phase I-III study participation and expertise in delivering complex and advanced therapy trials, including autologous dendritic cells, tumour-infiltrating lymphocytes (recruiting first patient in Europe to an international phase II metastatic Cervical Carcinoma study), and allogeneic therapies including viral-specific T-cells and mesenchymal stem cells (recruiting first-in-World patient to a Phase I Steroid Resistant Acute Graft Versus Host Disease trial)